Clinical Trial of TQH2722 Injection in Patients With Seasonal Allergic Rhinitis
Status:
COMPLETED
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
To evaluate TQH2722 injection in all patients receiving background treatment with mometasone furoate nasal spray (MFNS) and loratadine. The efficacy, safety and immunogenicity of the solution in patients with seasonal allergic rhinitis compared with placebo are expected to include 168 patients with confirmed seasonal allergic rhinitis (SAR) who have failed to respond to standard treatments.
Phase:
PHASE2
Details
Lead Sponsor:
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.